Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy

Introduction and Objectives. An elevated neutrophil-to-lymphocyte ratio (NLR) has been suggested to be associated with a poor prognosis in several cancers. We evaluated the utility of an elevated NLR as a biomarker to predict the prognosis of metastatic castration-resistant prostate cancer (mCRPC) p...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2017-01, Vol.2017 (2017), p.1-5
Main Authors: Teranishi, Jun-ichi, Makiyama, Kazuhide, Kishida, Takeshi, Udagawa, Koichi, Kobayashi, Kazuki, Miyoshi, Yasuhide, Yao, Masahiro, Uemura, Hiroji, Izumi, Koji, Yokomizo, Yumiko, Tatenuma, Tomoyuki, Abe, Koichi, Jikuya, Ryosuke, Yamashita, Daisuke, Kawahara, Takashi, Uemura, Koichi, Yumura, Yasushi
Format: Article
Language:English
Subjects:
Aged
Analysis
Biomarkers
Cancer
Cancer therapies
Castration
Chemotherapy
Disease-Free Survival
Drug therapy
Health hazards
Humans
Inflammation
Institutions
Lymph nodes
Lymphocyte Count
Lymphocytes
Male
Medical prognosis
Metastases
Metastasis
Middle Aged
Multivariate analysis
Neutrophils
Patients
Prognosis
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - blood
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - mortality
Retrospective Studies
Survival Rate
Taxoids - administration & dosage
Urology
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction and Objectives. An elevated neutrophil-to-lymphocyte ratio (NLR) has been suggested to be associated with a poor prognosis in several cancers. We evaluated the utility of an elevated NLR as a biomarker to predict the prognosis of metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel (CBZ). Methods. We analyzed 47 patients who received CBZ chemotherapy for mCRPC in our institutions. The NLR was calculated using the neutrophil and lymphocyte counts before CBZ chemotherapy. We determined the NLR cut-off value based on the sensitivity and specificity levels derived from area under the receiver operator characteristic curves for death. A multivariate analysis was performed to investigate the association between the NLR and the prognosis. Results. The median overall survival (OS) after CBZ was 10.0 months (range: 6.3–13.2). The median OS was shorter in patients with a high NLR (≥3.83) than in those with a low NLR (
ISSN:2314-6133
2314-6141
DOI:10.1155/2017/7538647